{"filing":{"accession_number":"0001171843-26-005908","cik":"0001114448","ticker":"NVSEF","company_name":"NOVARTIS AG","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"f6k_090826.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1114448/000117184326005908/f6k_090826.htm"},"events":[{"id":31711,"run_id":29114,"accession_number":"0001171843-26-005908","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Novartis announced that its Phase III HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1) failed to meet its primary endpoint of video hand opening time (vHOT), though secondary endpoints showed some clinical activity. This is a material clinical trial failure for an investigational therapy in Novartis's neuromuscular pipeline acquired through Avidity Biosciences. While the company maintains its 5-6% sales CAGR guidance and continues advancing other AOC therapies (del-zota and del-brax), the HARBOR failure represents a significant setback in a high-unmet-need indication and would affect investor assessment of the pipeline's value and development strategy.","company_name":"NOVARTIS AG","ticker":"NVSEF","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":34672,"accession_number":"0001171843-26-005908","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Novartis announced that its Phase III HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1) failed to meet its primary endpoint of video hand opening time (vHOT), though secondary endpoints showed some clinical activity. This is a material clinical trial failure for an investigational therapy in Novartis's neuromuscular pipeline acquired through Avidity Biosciences. While the company maintains its 5-6% sales CAGR guidance and continues advancing other AOC therapies (del-zota and del-brax), the HARBOR failure represents a significant setback in a high-unmet-need indication and would affect investor assessment of the pipeline's value and development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T10:07:54.580435+00:00","company_name":"NOVARTIS AG","ticker":"NVSEF","filing_date":"2026-09-08"}]}